Luca Testa1, Azeem Latib2, Federico De Marco2, Marco De Carlo2, Claudia Fiorina2, Rocco Montone2, Mauro Agnifili2, Marco Barbanti2, Anna Sonia Petronio2, Giuseppe Biondi Zoccai2, Federica Ettori2, Silvio Klugmann2, Corrado Tamburino2, Nedy Brambilla2, Antonio Colombo2, Francesco Bedogni2. 1. From the Department of Cardiology, IRCCS Pol San Donato, San Donato Milanese, Milan, Italy (L.T., R.M., M.A., N.B., F.B.); Interventional Cardiology Unit, Department of Cardiology, San Raffaele Hospital and EMO-GVM Centro Cuore Columbus, Milan, Italy (A.L., A.C.); Department of Cardiology, Niguarda Ca Granda Hospital, Milan, Italy (F.D.M., S.K.); Cardiothoracic and Vascular Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy (M.D.C., A.S.P.); Cardiothoracic Department, Spedali Civili, Brescia, Italy (C.F., F.E.); Department of Cardiology, Ferrarotto Hospital, Catania, Italy (M.B., C.T.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy (G.B.Z.); and Department of AngioCardioNeurology, IRCCS Neurome, Pozzilli, Italy (G.B.Z.). luctes@gmail.com. 2. From the Department of Cardiology, IRCCS Pol San Donato, San Donato Milanese, Milan, Italy (L.T., R.M., M.A., N.B., F.B.); Interventional Cardiology Unit, Department of Cardiology, San Raffaele Hospital and EMO-GVM Centro Cuore Columbus, Milan, Italy (A.L., A.C.); Department of Cardiology, Niguarda Ca Granda Hospital, Milan, Italy (F.D.M., S.K.); Cardiothoracic and Vascular Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy (M.D.C., A.S.P.); Cardiothoracic Department, Spedali Civili, Brescia, Italy (C.F., F.E.); Department of Cardiology, Ferrarotto Hospital, Catania, Italy (M.B., C.T.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy (G.B.Z.); and Department of AngioCardioNeurology, IRCCS Neurome, Pozzilli, Italy (G.B.Z.).
Abstract
BACKGROUND: Severe pulmonary hypertension (PH) is considered to negatively affect the outcome after transcatheter aortic valve replacement. However, a clear understanding of the pattern, evolution, and clinical impact of different grades of PH in this setting is lacking. METHODS AND RESULTS: A total of 990 consecutive patients were enrolled in 6 high-volume centers and analyzed as follows: group 1, systolic pulmonary artery pressure (sPAP) <40 mm Hg (346 patients; 35%); group 2, sPAP 40 to 60 mm Hg (426 patients; 43%); and group 3, sPAP >60 mm Hg (218 patients; 22%). At 1 month, mortality rate did not differ across the groups. When compared with groups 1 and 2, patients in group 3 had a higher-rate of New York Heart Association 3 to 4 (26% versus 12% and 10%), and a higher-rate of hospitalization for heart failure (7% versus 3% and 3%). At 1 year, when compared with patients in group 1, patients in group 2 and 3 had both a higher overall mortality (hazard ratio [HR], 1.5 [1.3-3.2]; P=0.01 and HR, 2.3 [1.8-2.8]; P=0.001) and a higher cardiac mortality (HR, 1.3 [1.1-2.1]; P=0.01 and HR, 1.7 [1.3-2.5]; P=0.002). After 1 month, the sPAP decreased ≥15 mm Hg in 32% and 35% of the patients in groups 2 and 3. Baseline sPAP >60 mm Hg (HR, 1.6 [1.1-2.3]; P=0.03) and, in a larger extent, a persistent severe PH after 1 month (HR, 2.4 [1.5-2.8]; P=0.004), independently predicted 1-year mortality, whereas the 1-month reduction of the sPAP did not. CONCLUSIONS: The persistence of severe PH after transcatheter aortic valve replacement is a stronger predictor of 1-year mortality than baseline severe PH. The early reduction of sPAP is not associated with a reduced mortality. The benefit of transcatheter aortic valve replacement in terms of quality of life is substantial in patients with and without a reduction of sPAP at early follow-up.
BACKGROUND: Severe pulmonary hypertension (PH) is considered to negatively affect the outcome after transcatheter aortic valve replacement. However, a clear understanding of the pattern, evolution, and clinical impact of different grades of PH in this setting is lacking. METHODS AND RESULTS: A total of 990 consecutive patients were enrolled in 6 high-volume centers and analyzed as follows: group 1, systolic pulmonary artery pressure (sPAP) <40 mm Hg (346 patients; 35%); group 2, sPAP 40 to 60 mm Hg (426 patients; 43%); and group 3, sPAP >60 mm Hg (218 patients; 22%). At 1 month, mortality rate did not differ across the groups. When compared with groups 1 and 2, patients in group 3 had a higher-rate of New York Heart Association 3 to 4 (26% versus 12% and 10%), and a higher-rate of hospitalization for heart failure (7% versus 3% and 3%). At 1 year, when compared with patients in group 1, patients in group 2 and 3 had both a higher overall mortality (hazard ratio [HR], 1.5 [1.3-3.2]; P=0.01 and HR, 2.3 [1.8-2.8]; P=0.001) and a higher cardiac mortality (HR, 1.3 [1.1-2.1]; P=0.01 and HR, 1.7 [1.3-2.5]; P=0.002). After 1 month, the sPAP decreased ≥15 mm Hg in 32% and 35% of the patients in groups 2 and 3. Baseline sPAP >60 mm Hg (HR, 1.6 [1.1-2.3]; P=0.03) and, in a larger extent, a persistent severe PH after 1 month (HR, 2.4 [1.5-2.8]; P=0.004), independently predicted 1-year mortality, whereas the 1-month reduction of the sPAP did not. CONCLUSIONS: The persistence of severe PH after transcatheter aortic valve replacement is a stronger predictor of 1-year mortality than baseline severe PH. The early reduction of sPAP is not associated with a reduced mortality. The benefit of transcatheter aortic valve replacement in terms of quality of life is substantial in patients with and without a reduction of sPAP at early follow-up.
Authors: Ahmad Masri; Islam Abdelkarim; Michael S Sharbaugh; Andrew D Althouse; Jeffrey Xu; Wei Han; Stephen Y Chan; William E Katz; Frederick W Crock; Matthew E Harinstein; Dustin E Kliner; Forozan Navid; Joon S Lee; Thomas G Gleason; John T Schindler; João L Cavalcante Journal: Heart Date: 2017-09-29 Impact factor: 5.994
Authors: Michael V Genuardi; Daniel Shpilsky; Adam Handen; Gabrielle VanSpeybroeck; Ann Canterbury; Michael Lu; Kayle Shapero; Ricardo A Nieves; Floyd Thoma; Suresh R Mulukutla; João L Cavalcante; Stephen Y Chan Journal: J Am Heart Assoc Date: 2021-02-18 Impact factor: 5.501
Authors: Micha T Maeder; Lukas Weber; Marc Buser; Marc Gerhard; Philipp K Haager; Francesco Maisano; Hans Rickli Journal: Front Cardiovasc Med Date: 2018-05-23
Authors: Javier Bermejo; Ana González-Mansilla; Teresa Mombiela; Ana I Fernández; Pablo Martínez-Legazpi; Raquel Yotti; Rocío García-Orta; Pedro L Sánchez-Fernández; Mario Castaño; Javier Segovia-Cubero; Pilar Escribano-Subias; J Alberto San Román; Xavier Borrás; Angel Alonso-Gómez; Javier Botas; María G Crespo-Leiro; Sonia Velasco; Antoni Bayés-Genís; Amador López; Roberto Muñoz-Aguilera; Manuel Jiménez-Navarro; José R González-Juanatey; Arturo Evangelista; Jaime Elízaga; Javier Martín-Moreiras; José M González-Santos; Eduardo Moreno-Escobar; Francisco Fernández-Avilés Journal: J Am Heart Assoc Date: 2021-01-05 Impact factor: 5.501